Summary
Twenty patients with refractory heart failure NYHA class IV were randomly assigned to infusion therapy with 9.25 μg/kg/min dobutamine over 24 hours or placebo. Eight infusions over a 4-week period were performed in the hospital; between infusions breaks of 3 days were scheduled. A dose titration was performed before study during which dobutamine was infused at 2.5 μg/kg/min and increased by 2.5 μg/kg/min steps every 15 minutes up to a maximum dosage of 10 μg/kg/min. After dobutamine, exercise duration on the treadmill stress test increased from 177±110 seconds to 251 ±120 seconds (p<0.05). The heart-rate response to exercise increased (91±20 to 116±26 beats/min at baseline, 88±17 to 132±26 beats/min after therapy). Body weight decreased from 70.9±15.5 to 68.9±14.2 kg (p<0.03). On placebo, no significant changes were evident. Systolic time intervals and hemodynamic parameters showed only minor and not significant changes in both groups. No excess mortality emerged during intermittent dobutamine therapy. No clinical or hemodynamic signs of tolerance development were evident during control assessment 3 days after the last infusion. Intermittent therapy with dobutamine seems to be a promising concept in the management of refractory severe heart failure.
Similar content being viewed by others
References
Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration cooperative study. N Engl J Med 1986;314:1547–1552.
Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429–1435.
Dies F, Krell MJ, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure (abstract). Circulation 1986;74 (Suppl II):II38.
Leier CV, Webel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation 1977;56:468–472.
Hodgson J, Aja M, Sorkin RP. Intermittent ambulatory dobutamine infusions for patients awaiting cardiac transplantation. Am J Cardiol 1984;53:375–376.
Applefeld MM, Newman KA, Grove WR, et al. Intermittent continuous outpatient dobutamine infusion in the management of congestive heart failure. Am J Cardiol 1983;51: 455–458.
Unverferth DV, Magorien RD, Lewis RP, Leier CV. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1980;100:622–630.
Krell MJ, Kline EM, Bates ER, et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986;112:787–791.
Yang SS, Bentivoglio LG, Maranhao V, Goldberg H. From cardiac catheterization data to hemodynamic parameters. Davies, Philadelphia: 1972.
Weissler AM. Systolic time intervals. N Engl J Med 1977;296:321–324.
Tuttle RR, Mills J. Dobutamine: Development of a new catecholamine to selectively increase contractility. Circ Res 1975;36:185–196.
Kupper W, Waller D, Hanrath P, Bleifeld W. Hemodynamic and cardiac metabolic effects of inotropic stimulation with dobutamine in patients with coronary artery disease. Eur Heart J 1982;3:29–34.
Böhm M, Beuckelmann D, Brown L, et al. Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased humam myocardium. Eur Heart J 1988;9:844–852.
Cohn JN. Plasma norepinephrine as a guide to prognosis in patients with congestive heart failure. N Engl J Med 1984;311:819–823.
Uretsky BF, Generalovich T, Verbalis JE, et al. Comparative hemodynamic and humoral response of enoximone and dobutamine in severe congestive heart failure. Am J Cardiol 1986;58:110–116.
Melot C, Hallemans R, Naeije R, et al. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984;130:612–616.
Maskin CS, Forman R, Sonnenblick EH, et al. Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure. Am J Cardiol 1983;51:177–182.
Unverferth DV, Leier CV, Magorian R, et al. Improvement of human myocardial mitochondria after dobutamine. A quantitative ultrastructural study. J Pharmacol Exp Ther 1980;215:527–532.
Erlemeier HH, Kupper W, Bleifeld W. Lack of tolerance development after long-term administration of the partial beta-adrenoceptor agonist xamoterol. Cardiology 1990;77: 30–39.
Erlemeier HH, Kupper W, Bleifeld W. Exercise capacity, arrhythmias, humoral and chemical parameters during long-term therapy with xamoterol. Int J Cardiol 1990;28: 197–208.
Erlemeier HH, Kupper W, Bleifeld W. Hemodynamic and humoral effects of xamoterol during acute and long-term therapy with regard to left ventricular function after xamoterol. J Appl Cardiol 1990;5:159–171.
The German and Austrian Xamoterol Study Group. Double blind placebo controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet 1988;1:489–493.
Drexler H, Banhardt U, Meinertz T, et al. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. Circulation 1989;79:491–502.
Leimbach WN, Wallin BG, Victor RG, et al. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;73:913–919.
Osterziel KJ, Dietz R, Schmid W, Kübler W. Reflektorische regulation der herzfrequenz bei herzinsuffizienten patienten. Z Kardiol 1988;77:576–581.
Goldstein RE, Beiser GD, Stampfer M, Epstein SE. Impairment of autonomically mediated heart rate control in patients with cardiac dysfunction. Circ Res 1975;36:571–578.
Unverferth DV, Blanford M, Kates RE, Leier CV. Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med 1980;69:262–266.
Erlemeier HH, Kupper W, Hamm CW, Bleifeld W. Toleranzent wicklung während einwöchiger Dobutamin-Behandlung. Dtsch Med Wschr 1986;111:1010–1016.
Majerus TC, Dasta JF, Bauman JL, et al. Dobutamine: Ten years later. Pharmacotherapy 1989;9:245–259.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Erlemeier, HH., Kupper, W. & Bleifeld, W. Intermittent infusion of dobutamine in the therapy of severe congestive heart failure-long-term effects and lack of tolerance. Cardiovasc Drug Ther 6, 391–398 (1992). https://doi.org/10.1007/BF00054187
Issue Date:
DOI: https://doi.org/10.1007/BF00054187